Showing 3,141 - 3,160 results of 21,342 for search '(( significant decrease decrease ) OR ( significance ((teer decrease) OR (a decrease)) ))', query time: 0.52s Refine Results
  1. 3141

    UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
  2. 3142
  3. 3143
  4. 3144

    Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

    Published 2024
    “…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”
  5. 3145

    Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

    Published 2024
    “…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”
  6. 3146
  7. 3147
  8. 3148

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  9. 3149

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  10. 3150

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  11. 3151

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  12. 3152

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  13. 3153

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  14. 3154

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  15. 3155

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  16. 3156
  17. 3157
  18. 3158
  19. 3159
  20. 3160